Physician profile
Ross B Chod
NPI 1801158548
$10,017.90
in general payments reported to CMS, 2019-2025
26 companies · $2,487 in 2025
The $2,487 reported for 2025 was more than what 84% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $52.49 · 2021: $583 · 2022: $682 · 2023: $1,508 · 2024: $4,290 · 2025: $2,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,466 · Travel and Lodging: $1,591 · Entertainment: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,465.61 |
| Travel and Lodging | $1,590.88 |
| Entertainment | $229.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $1,915.23 | 2021-2024 | |
| Genentech USA, INC. | $1,296.03 | 2023-2025 | Vabysmo, Susvimo |
| Ocular Therapeutix, INC. | $1,164.17 | 2024-2025 | Dextenza |
| Abbvie INC. | $1,159.70 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Apellis Pharmaceuticals, INC. | $613.44 | 2023-2025 | Syfovre |
| Astellas Pharma US INC | $610.27 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $596.77 | 2022-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $516.46 | 2019-2025 | Eylea Hd, Eylea |
| Optos, INC. | $337.66 | 2020-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Biogen, INC. | $299.55 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $278.48 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $209.37 | 2022-2023 | Stellaris Elite |
| Dutch Ophthalmic, USA | $206.23 | 2021 | |
| Notal Vision, INC. | $149.60 | 2021-2022 | |
| Carl Zeiss Meditec USA, INC. | $127.74 | 2021-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $111.29 | 2025 | Iluvien, Yutiq |
| Harrow Eye, LLC | $105.49 | 2025 | Triesence, Iheezo |
| Coherus Oncology, INC. | $100.41 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $97.61 | 2025 | Acthar |
| Biotissue Holdings INC. | $70.96 | 2022 | |
| Astellas Pharma Global Development | $22.19 | 2024 | Izervay |
| Vyera Pharmaceuticals, LLC | $15.07 | 2019 | |
| Allergan, INC. | $14.18 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Chod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.